Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$60.67 - $89.12 $279,082 - $409,952
-4,600 Reduced 86.79%
700 $47,000
Q4 2023

Jan 18, 2024

BUY
$38.62 - $72.18 $127,445 - $238,194
3,300 Added 165.0%
5,300 $331,000
Q1 2023

Apr 12, 2023

BUY
$41.0 - $56.12 $82,000 - $112,240
2,000 New
2,000 $90,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.97B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Brave Asset Management Inc Portfolio

Follow Brave Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brave Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Brave Asset Management Inc with notifications on news.